Novo has a big pricing decision to make with semaglutide. Which way will it go?

Novo Nordisk
Novo Nordisk hasn't yet decided whether to price oral semaglutide on par with injectable GLP-1 therapies or with other diabetes pills, its CEO says. (Novo Nordisk)

As Novo Nordisk’s highly anticipated semaglutide pill nears the market, the company has a big decision to make: at what price?

Because oral semaglutide would be the first GLP-1 tablet, Novo has to “make some technical considerations,” CEO Lars Fruergaard Jørgensen said in an interview. “Do we price as a GLP-1, or do we price more as a tablet, or somewhere in between?”

On the one hand, it’s more expensive to produce a tablet than it is to produce one injection, because tablets require more active ingredient, he said.


Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

But on the other, a lower price could potentially help the Novo pill snatch share from its in-class competitors—with Eli Lilly’s Trulicity representing the heavyweight among them—and even gain ground against oral SGLT2 treatments.

RELATED: Novo CEO: Expect U.S. diabetes drug prices to continue their downward spiral next year

Of course, the price the Danish drugmaker ultimately sets for semaglutide won’t include rebates—and rebates could be taking a bigger chunk out of GLP-1 sales come 2019, Bernstein analyst Wimal Kapadia pointed out in a recent note to clients.

While Novo said on its second-quarter earnings call that it expects a U.S. price drop for 2019 to be “predominantly” driven by basal insulins, it “did not clarify” whether GLP-1 pricing would decline, too.

As he noted, though, with GLP-1s, “it is a volume game”—and volume is exactly what Novo’s going for. In addition to blockbuster injectable Victoza, it already has a once-weekly injectable version of semaglutide—known as Ozempic—rolling out in the category with a price tag of $729.40 per pen.

RELATED: Novo Nordisk results show GLP-1s are job 1. Can its crucial Ozempic launch deliver?

On that front, Jørgensen says, things are going well. The company now has better than 60% access for Ozempic in the U.S., and it continues to switch reps over from Victoza to Ozempic as that access grows.

“We strike when we have access,” he said, adding that reps “stay on Victoza until access is obtained.”

Suggested Articles

Only months after a game-changing new approval for Vascepa, Amarin has lost a key fight over its patents—and now it's scrambling to respond.

Move over, Roche. There’s a new small cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.